Crinecerfont

Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency^[1][2]. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. IC50 & Target:IC50: CRF1 receptor In Vivo:Crinecerfont (SSR-125543) (20 mg/kg; i.p.; daily; 5 weeks) improves hypothalamic-pituitary-adrenal (HPA) axis negative feedback sensitivity in chronically stressed mice but exacerbates their basal circadian corticosterone secretion, and does not alter HPA axis circadian activity or negative feedback sensitivity in non-stressed control mice^[1].